RxSight, Inc.

NasdaqGM:RXST Stok Raporu

Piyasa değeri: US$282.3m

RxSight Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

RxSight şirketinin kazançları yıllık ortalama -10.2% oranında azalırken, Medical Equipment sektörünün kazançları yıllık 10.1% oranında artan oldu. Gelirler yıllık ortalama 41.8% oranında artan oldu.

Anahtar bilgiler

-10.18%

Kazanç büyüme oranı

-9.73%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi8.90%
Gelir büyüme oranı41.80%
Özkaynak getirisi-14.13%
Net Marj-28.96%
Sonraki Kazanç Güncellemesi06 May 2026

Yakın geçmiş performans güncellemeleri

Recent updates

RXST: Future Returns Will Rely On Reset 2026 Revenue Guidance

Analysts have trimmed RxSight's fair value estimate from about $10.21 to $9.93, reflecting recent price target adjustments after Q4 results and updated 2026 revenue guidance. Analyst Commentary Recent Street research around RxSight centers on updated price targets and the new 2026 revenue outlook, with opinions clustering around a more cautious but still engaged stance.

RXST: Future Returns Will Rely On New CFO And 2026 Revenue Guidance

Analysts now see RxSight's fair value edging up to about $10.21 per share from roughly $10.06, reflecting recent price target moves clustered around $9 to $10 as they incorporate updated 2026 guidance, Q4 results and leadership changes into their models. Analyst Commentary Recent research paints a mixed picture around RxSight, with price targets clustered around the high single digits and ratings generally sitting in the middle of the scale.

RXST: Future Returns Will Hinge On New CFO And 2026 Guidance

RxSight's updated fair value estimate has edged slightly lower, in line with Street price targets drifting from around $10 to a range centered near $9 to $10, as analysts factor in refreshed models, 2026 revenue guidance of $120M to $135M, and a mix of target cuts and raises that still cluster around neutral ratings. Analyst Commentary Recent research keeps RxSight broadly in neutral territory, with modest target changes reflecting updated revenue models, the new 2026 guidance range of $120M to $135M, and reactions to management changes.

RXST: Future Returns Will Hinge On New CFO And Execution Quality

Analysts have nudged their blended price target on RxSight lower to about $10.17 from $10.39, reflecting updated views on revenue growth, margins, and future P/E after recent neutral ratings and mixed target moves in the $9 to $10 range. Analyst Commentary Recent research paints a mixed picture for RxSight, with most firms holding neutral ratings and fine tuning their targets in a relatively tight range around the current blended estimate.

Is This Lens Maker Mispriced? A Blind Spot in Plain Sight

RxSight (NASDAQ: RXST), maker of the only cataract lens that can be adjusted post-surgery, could be undervalued by an eye-popping margin More than 70% of RxSight Light Adjustable Lens (LAL) patients reported 20/20 or better vision after receiving the lens. Only 36.3% of non-adjustable lens patients reported the same.

RXST: Future Returns Will Depend On New CFO And Execution Quality

Analysts have raised their average price target on RxSight by $1, citing the recent Piper Sandler move, a neutral initiation that adds coverage breadth, and supportive commentary around the new CFO appointment as reasons for a slightly refined outlook on growth, profitability, and future P/E expectations. Analyst Commentary Recent Street research on RxSight centers on how the new CFO, updated guidance commentary, and modest target changes feed into expectations for execution quality and valuation support.

RXST: Future Returns Will Hinge On New CFO And Execution Confidence

Analysts have nudged their price targets on RxSight modestly higher, with updated models pointing to slightly stronger revenue growth and profit margins and a marginally lower discount rate, while some recent research highlights a move to a $10 target and views the new CFO appointment as supportive of the story. Analyst Commentary Recent research on RxSight reflects a mix of cautious optimism and lingering questions around execution, valuation and the setup after recent share price moves.

RXST: Future Returns Will Depend On Comfortable Revenue And New CFO Execution

Analysts nudged their fair value estimate for RxSight slightly higher to about $10.39 from $10.33, citing better than anticipated recent quarters, a new CFO appointment they view positively, and Street research highlighting revenue that came in ahead of prior expectations, with longer term revenue forecasts described as comfortable. Analyst Commentary Recent Street research paints a mixed but generally constructive picture around RxSight, with attention on execution in recent quarters, the new CFO appointment, and how current revenue trends line up with existing expectations.

We're Hopeful That RxSight (NASDAQ:RXST) Will Use Its Cash Wisely

Jan 10
We're Hopeful That RxSight (NASDAQ:RXST) Will Use Its Cash Wisely

RXST: Future Returns Will Hinge On Sustaining Comfortable Revenue Expectations

Analysts lifted their fair value estimate for RxSight to about $10.33 from $9.89 after a recent price target increase to $10.00. They pointed to a quarter they viewed as better than feared, with revenue of $30m above prior estimates and current Street revenue expectations that they describe as comfortable.

RXST: Future Returns Will Depend On Sustaining Recent Revenue Outperformance

Analysts modestly raised their price target on RxSight to $10 from $8, citing a quarter that exceeded revenue expectations and growing confidence that current Street forecasts for 2026 sales are achievable. Analyst Commentary Analysts are digesting the stronger than expected quarter and reassessing the balance between upside potential and execution risks for RxSight.

RxSight, Inc.'s (NASDAQ:RXST) 28% Price Boost Is Out Of Tune With Revenues

Dec 12
RxSight, Inc.'s (NASDAQ:RXST) 28% Price Boost Is Out Of Tune With Revenues

RXST: Future Performance Will Hinge On Sustaining Outperformance Amid Lawsuit Uncertainty

Analysts have increased their price target for RxSight by $2 to $10, citing stronger than expected quarterly revenue performance and a favorable outlook for future estimates. Analyst Commentary Analysts have shared insights following the latest quarterly results for RxSight, highlighting both the optimistic outlook and areas of caution as the company navigates its growth trajectory.

RXST: Future Performance Will Depend On Sustained Revenue Execution And Demand Consistency

Analysts have increased their price target for RxSight to $9.67 from $8.89, citing strong quarterly revenue performance well above expectations and expressing confidence in future revenue estimates. Analyst Commentary Following RxSight's latest quarterly results, analysts have highlighted several factors influencing their revised outlook for the company’s valuation and future performance.

Lacklustre Performance Is Driving RxSight, Inc.'s (NASDAQ:RXST) 25% Price Drop

Oct 11
Lacklustre Performance Is Driving RxSight, Inc.'s (NASDAQ:RXST) 25% Price Drop

The Bottom Fishing Club - RxSight: A Ski-Jump Reversal Pattern?

Sep 22

Entry Into European And Asian Markets Will Unlock New Opportunities

RxSight’s consensus price target has been significantly reduced to $8.89 as analysts cite ongoing quarterly misses, slower customer adoption, plateauing utilization rates, and uncertainty around commercial strategy execution. Analyst Commentary Multiple bearish analysts cite consecutive quarterly misses and lowered guidance as primary concerns impacting RxSight's outlook.

Investors Don't See Light At End Of RxSight, Inc.'s (NASDAQ:RXST) Tunnel And Push Stock Down 39%

Aug 07
Investors Don't See Light At End Of RxSight, Inc.'s (NASDAQ:RXST) Tunnel And Push Stock Down 39%

Time To Worry? Analysts Just Downgraded Their RxSight, Inc. (NASDAQ:RXST) Outlook

Jul 19
Time To Worry? Analysts Just Downgraded Their RxSight, Inc. (NASDAQ:RXST) Outlook

The Price Is Right For RxSight, Inc. (NASDAQ:RXST)

Jun 18
The Price Is Right For RxSight, Inc. (NASDAQ:RXST)
User avatar

South Korea And UK Approvals Will Expand Market Adoption

International expansion and regulatory approvals are poised to significantly boost revenue by entering new markets and enhancing clinical support.

RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business

Apr 04
RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business

RxSight, Inc. (NASDAQ:RXST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

Mar 08
RxSight, Inc. (NASDAQ:RXST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

RxSight, Inc. (NASDAQ:RXST) Just Reported, And Analysts Assigned A US$44.80 Price Target

Feb 28
RxSight, Inc. (NASDAQ:RXST) Just Reported, And Analysts Assigned A US$44.80 Price Target

The Price Is Right For RxSight, Inc. (NASDAQ:RXST)

Dec 06
The Price Is Right For RxSight, Inc. (NASDAQ:RXST)

RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye

Nov 29

We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth

Sep 04
We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth

Investing In The Future Of Cataract Surgery: The RxSight Advantage

Aug 13

With A 27% Price Drop For RxSight, Inc. (NASDAQ:RXST) You'll Still Get What You Pay For

Aug 03
With A 27% Price Drop For RxSight, Inc. (NASDAQ:RXST) You'll Still Get What You Pay For

Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching

Jul 12
Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching

RxSight: Great Business Model, Stretched Valuations

Jul 10

A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)

Jun 20
A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)

RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results

May 09
RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results

RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business

May 05
RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business

RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation

May 01

Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price

Apr 16
Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price

Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?

Mar 24
Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?

RxSight Stock: Time To Refocus Following Eye Watering Rally

Jan 16

RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

Jan 09
RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth

Dec 21
We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth

Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%

Nov 24
Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%

Gelir ve Gider Dağılımı

RxSight nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGM:RXST Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
31 Dec 25134-3911339
30 Sep 25142-3611339
30 Jun 25147-3211239
31 Mar 25148-2710737
31 Dec 24140-2710234
30 Sep 24128-319432
30 Jun 24115-378831
31 Mar 24101-448230
31 Dec 2389-497529
30 Sep 2377-557028
30 Jun 2367-596527
31 Mar 2358-626226
31 Dec 2249-675926
30 Sep 2241-675525
30 Jun 2235-634924
31 Mar 2228-594124
31 Dec 2123-493324
30 Sep 2119-152624
30 Jun 211742124
31 Mar 2115171723
31 Dec 201531522
31 Dec 192261530

Kaliteli Kazançlar: RXST şu anda kârlı değil.

Büyüyen Kar Marjı: RXST şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: RXST kârlı değildir ve zararlar son 5 yılda yılda 10.2% oranında artmıştır.

Büyüme Hızlandırma: RXST 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: RXST kârlı olmadığından, geçmiş yıl kazanç büyümesinin Medical Equipment sektörüyle ( 7.5% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: RXST hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -14.13% ) sahiptir.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/04/30 09:48
Gün Sonu Hisse Fiyatı2026/04/29 00:00
Kazançlar2025/12/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

RxSight, Inc. 15 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Travis SteedBofA Global Research
Michael GormanBTIG
Xuyang LiJefferies LLC